Serum leptin düzeyinin depresif bozukluk alt tipleriyle ilişkisi

Amaç: Bu çalışmada, depresif bozukluklarda DSM-III-R tanı ölçütlerindeki alt tiplerine göre serum leptin düzeyi ve leptinin depresif bozukluklar üzerine olası etkilerinin araştırılması amaçlandı, yöntem: Çalışmaya 101 depresif bozukluğu olan hasta ve 35 sağlıklı kontrol alındı. Hastalar majör depresif epizod (MDE), distimik bozukluk (DB), başka türlü adlandırılmayan depresif bozukluk (BTADB) şeklinde gruplandırıldı. Hastalara DSM-III-R için yapılandırılmış klinik görüşme formu uygulanarak DSM-III-R'ye göre tanı konduktan sonra depresyonun şiddeti Hamilton Depresyon Derecelendirme Ölçeği (HDDÖ) ile değerlendirildi. Hasta ve kontrollerde beden kitle indeksi (BKİ) ölçümüyle beraber 12 saatlik açlık sonrası sabah 08.00-09.00 saatlerinde serum leptin, kortizol, 6H, insülin ve lipid prof iline bakıldı. Bulgular: Majör depresif epizod, distimik bozukluk, başka türlü adlandlrılamayan depresif bozukluk hasta grupları ve kontrol grubu arasında karşılaştırmalarda, serum leptin düzeyinin yanı sıra serum kortizol, GH, insülin, lipid profil düzeyleri yönünden de istatistiksel bir fark bulunmadı. Hasta ve kontrol gruplarında, serum leptin düzeyi ve BKÎ arasında güçlü bir pozitif korelasyon bulundu. Tartışma: Çalışmamızda depresif hasta gruplarında serum leptin düzeyinin etkilendiğini destekleyen anlamlı sonuçlar bulunmamıştır

The association between serum leptin and the subtypes of depressive disorder

Objective: in this study, we planned to evaluate the association between serum leptin and depression (according to DSM-III-R subtypes). Methods: The study was consisted of 101 depressive patients and 35 healthy controls. The patients were assigned to subgroups as majör depressive episode, dysthymic disorder, not other specified depressive disorder. The patients were assessed by structured clinical interview for DSM-III-R and then, Hamilton Depression Rating Scale was administered to all patients. Body mass index was calculated for all subjects. Fasting serum leptin, cortisol, 6H, insülin and lipid levels were measured at 08.00-09.00, Result: With respect to serum leptin levels, there were no statistical differences among the patients with major depressive episode, dystymic disorder, not other specified depressive disorder and controls. With respect to serum cortisol, GH, insülin, lipid profile, there were no statistical differences among the patient groups and between the patients and controls. in ali patient groups and controls, there masstrongly positive correlation between serum teptin levels and BMI. Discussion: We suggest that there was no relation betıveen depressive subtypes and serum teptin levels

___

  • 1. Deuschle M, Blum WF, Englaro P, Schweiger U, Weber B, Pflaum CD ve ark: Plasma leptin in depressed patients and healthy controls. Hormone Metab Res 1996; 28:714-717.
  • 2. Yüksel N: Ruhsal Hastalıklar. İkinci baskı, Ankara, Çizgi Tıp Yayınevi, 2001.
  • 3. Auwerx J, Steals B: Leptin. Lancet. 1998; 351:737-742.
  • 4. Zukowska-Grojec Z: Neuropeptid I: a nowel sympathetic stress hormone and more. Ann N Y Acad Sci 1995; 771:219-233.
  • 5. Woods SC, Seeley RJ, Porte D Jr, Schwartz MW: Signal that regulate food intake and energy homeostasis. Science 1998; 280:1378-1383.
  • 6. Halifeoğlu İ, Üstündağ B, Canatan H: Multipl fonksiyonlu bir adipoz doku hormonu: leptin. Fırat Tıp Dergisi 2000; 4:67-75
  • 7. Heilig M, Soderpalm B, Engel JA, Widerlov E: Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 1989; 98:524-529.
  • 8. Stephens TW, Basinski M, Bristow PK: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995; 377:530-532.
  • 9. Suomalainen M, Mannistö PT: Lack of effect of leptin on the behaviour of mice predicting the level of anxiety and depression. Pharmacol Toxicol 1998; 83:139-142.
  • 10. Morley JE, Kraenzle D: Causes of weight loss in a community nursing home. J Am Geriatr Soc 1994; 42:583-585.
  • 11. Alexopoulos GS, Vrontou C, Kakuma T, Meyers BS, Young RC, Klausner E ve ark: Disability in geriatric depression. Am J Physiol 1995; 267:959-966.
  • 12. Kunugi H, Takei N, Aoki H, Nanko S: Low serum cholesterol in suicide attempters. Biol Psychiatry 1997; 41:196-200.
  • 13. Pentinen J: Pothesis: low serum cholesterol, suicide and interleukin 2. Am J Epidemiol 1995; 141:711-717.
  • 14. Kaplan LM: Leptin, obesity, and liver disease. Gastroenterology 1998; 115:997-1001
  • 15. Sinha M: Human leptin: the hormone of adipose tissue. Eur J Endocrinol 1997; 136:461-464.
  • 16. Amerikan Psikiyatri Birliği: Mental Bozuklukların Tanısal ve Sayımsal El Kitabı (DSM-III-R). Washington DC, APA Press, 1987.
  • 17. Sorias S, Saygılı R, Elbi H: DSM-III-R Yapılandırılmış Klinik Görüşmesi Türkçe Versiyonu (SCID) Kullanım Klavuzu. İzmir, Ege Üniversitesi Yayınevi, 1990.
  • 18. Akdemir A, Örsel S, Dağ İ, İşcan N, Özbay H: Hamilton Depresyon Derecelendirme Ölçeği’nin (HDDÖ) geçerliği, güvenirliği ve klinikte kullanımı. 3P Dergisi 1996; 4:251-259.
  • 19. Geldzus R, Mayr B, Horn R, Geisthovel F, von zur Mühlen A, Brabant G: Serum leptin and weight reduction in female obesity. Eur J Endocrinol 1996; 135:659-662.
  • 20. Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR, Kuijper JL: Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J Clin Endocrinol Metab 1997; 82:561-565.
  • 21. Saad MF, Damani S, Gingerich RL, Riad-Gabriel MG, Khan A, Boyadjian R ve ark: Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997; 82:579-584.
  • 22. Leroy P, Dessolin S, Villageois P, Moon BC, Friedman JM, Ailhaud G ve ark: Expression of ob gene in adipose cells. Regulation by insulin. J Biol Chem 1996; 271:2365-2368.
  • 23. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR ve ark: Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334:292-295.
  • 24. Anderson IM, Crook WS, Gartside CG, Fairburn CG, Cowen PJ: The effect of moderate weight loss on overnight growth hormone and cortisol secretion in healthy female volunteers. J Affect Dis 1989; 16:197-202.
  • 25. Papaspyrou-Rao S, Schneider SH, Petersen RN, Fried SK: Dexamethasone increases leptin expression in humans in vivo. J Clin Endocrinol Metab 1997; 82:1635-1637.
  • 26. Larsson H, Ahren B: Short-term dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women. J Clin Endocrinol Metab 1996; 81:4428-4432.
  • 27. Zakrzewska KE, Cusin I, Sainsbury A, Rohner-Jeanrenaud F, Jeanrenaud B: Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 1997; 46:717-719.
  • 28. Steiger A, Holsboer F: Nocturnal secretion of prolactin and cortisol and sleep EEG in patients with major endogenous depression during an acute episode and after full remission. Psychiatry Res 1997; 72:81-88.
  • 29. De Vos P, Saladin R, Auwerx J, Staels B: Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem 1995; 270:15958-15961.
  • 30. Murakami T, Iida M, Shima K: Dexamethasone regulates obese expression in isolated rat adipocyte. Biochem Biophs Res Commun 1996; 214:1260-1267.
  • 31. Antonijevic IA, Murck H, Frieboes R-M, Horn R, Brabant G, Steiger A: Elevatednocturnal profiles of serum leptin in patients with depression. J Psychiatric Res 1998; 32:403-410.
  • 32. Deuschle M, Schweiger U, Weber B, Gotthart U, Körner A, Schmieder J ve ark: Diurnal activity and pulsatility of the hypotalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997; 82:234-238.
  • 33. Smith FJ, Campfield A, Mischera JA, Ballon PS, Burn P: Feeding inhibition by neuropeptide Y. Nature 1996; 382:307.
  • 34. Campfield LA: Central mechanisms responsible for the actions OB protein (leptin) on food intake, metabolism and body energy storage. Front Horm Res 2000; 26:12-20.
  • 35. Raber J, Chen S, Mucke L, Feng L: Corticotropinreleasing factor and adrenocorticotropic hormone as potential central mediators of OB effects. J Biol Chem 1997; 272:15057-15060.
  • 36. Schwartz MW, Seely RJ, Campfield LA, Burn P, Baskin DG: Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996; 98:1101-1106.
  • 37. Glaum SR, Hara M, Bindokas VP, Lee CC, Polonsky KS, Bell GI ve ark: Leptin, obese gene product, rapidly modulates synaptic transmission in the hypothalamus. Mol Pharmacol 1996; 50:230-235.
  • 38. Hanson ES, Dallman MF: Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and hypothalamo-pituitary-adrenal axis. J Neuroendocrinol 1995; 7:273-279.
  • 39. Ordway GA, Stockmeier CA, Meltzer HY, Overholser JC, Jaconetta S, Widdowson PS: Neuropeptide Y in frontal cortes is not altered in major depression. J Neurochem 1995; 65:1646-1650.
  • 40. Licinio J, Mantzoros C, Negrao AB, Kaklamani V, Wong ML, Bongiorno PB ve ark: Synchronicity of frequently sampled 24-h concentrations of circulating leptin, luteinizing hormone and estradiol in healty women. Proc Natl Acad Sci 1998; 95:2541-2546.
  • 41. Özata M: Leptin, genetik ve moleküler biyoloji. Aktuel Tıp Dergisi 2001; 2:22-29.
  • 42. Dagogo-Jack S, Fanelli C, Paramore D, Brothers J, Landt M: Plasma leptin and insülin relationships in obese and non-obese humans. Diabetes 1996; 45:695-698.
  • 43. Kolaczynski JW, Nyce MR, Considine RV, Bolden G, Nolan JJ, Henry R ve ark: Acute and chronic effect of insulin on leptin production in humans. Studies in vi vo and in vitro. Diabetes 1996; 45:699-701.